Chemotherapy News and Research

Latest Chemotherapy News and Research

Study: Patients experience sleep apnea after opharyngeal cancer treatment

Nearly all patients who underwent surgery to treat oropharyngeal cancer experienced some degree of obstructive sleep apnea (OSA), according to new research presented at the 2009 American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting & OTO EXPO, in San Diego, CA.

7 Oct 2009

Combination of leukemia and breast cancer drugs inhibits cancer progression

When breast cancer spreads or metastasizes, it crashes through the body's protective fences. The disease becomes fatal when it travels outside the mammary ducts, enters the bloodstream and spreads to the bones, liver or brain.

7 Oct 2009

Stereotactic Radiosurgery for metastatic brain tumors reduces risks of learning and memory problems

Cancer patients who receive stereotactic radiosurgery (SRS) and whole brain radiation therapy (WBRT) for the treatment of metastatic brain tumors have more than twice the risk of developing learning and memory problems than those treated with SRS alone, according to researchers at The University of Texas M. D. Anderson Cancer Center.

7 Oct 2009

Scientists create new technology to improve detection of leukemia cells in bone marrow

Scientists have created a viable technology to improve the detection of leukemia cells in bone marrow.

7 Oct 2009

Scrapbooking Marathon to raise funds for breast cancer awareness and research

The 24-hour Survivor Crop Scrapbooking Marathon is back to raise funds for breast cancer awareness and research through Susan G. Komen for the Cure, San Diego.

7 Oct 2009

Pro-Pharmaceuticals closes $325,000 tranche of private placement; total raised to $3.8 million

Pro-Pharmaceuticals, Inc. (OTCBB: PRWP) (the “Company”), today announced that it has closed a $325,000 tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants. This tranche brings the total raised to date to approximately $3.8 million.

7 Oct 2009

iMedicor to market Access Pharmaceuticals' MuGard in North America

ACCESS PHARMACEUTICALS, INC. announced today that it had signed an agreement with iMedicor for the North American commercial launch of MuGard, its FDA approved mucoadhesive oral rinse for the management of oral mucositis and stomatitis caused by radiotherapy and/or chemotherapy.

6 Oct 2009

OncoGenex' OGX-011 receives additional FDA Fast Track Designation for treating metastatic prostate cancer

OncoGenex Pharmaceuticals, Inc. announced today that OGX-011, also known as custirsen sodium, received an additional Fast Track Designation from the U.S. Food & Drug Administration (FDA) for progressive metastatic prostate cancer in combination with first-line docetaxel treatment.

6 Oct 2009

New embolization technique offers better clinical outcomes in the treatment of liver cancer

The authors of a newly published paper in the September/October journal Vascular Disease Management conclude that the micro-bland embolization technique possible with Embozene(TM) Color-Advanced Microspheres leads to better clinical outcomes.

6 Oct 2009

NYBC encourages people to organize community blood drives

With the school season underway, New York Blood Center would like to encourage students, teachers and faculty to please organize blood drives at their schools, a process that teaches community service and leadership skills, and offers a learning experience for both students and the surrounding community.

6 Oct 2009

New fruit-flavored protein drinks for nutritionally challenged

The Isopure Company, LLC. announced today the U.S. launch of Isopure Plus - a new line of clear, fruit-flavored protein drinks offering seniors and people with nutritional challenges a great-tasting, easy-to-digest alternative to thick milkshake-like protein formulations.

6 Oct 2009

Elekta Impac Software to demonstrate its integrated oncology EHR, MOSAIQ at EHR Symposium

Elekta Impac Software has been selected to demonstrate at the 2009 American Society of Clinical Oncology (ASCO) Electronic Health Records (EHR) Symposium: Harnessing the EHR, From Incentives to Sustainability, October 6-7, in San Francisco, California.

From Elekta 6 Oct 2009

EP-100 membrane-disrupting peptide drug for cancer being tested at TCRS

A new drug designed to "seek and destroy" common cancers such as breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers is being tested at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare.

6 Oct 2009

Two-thirds of tonsil tumour samples show evidence of HPV-16 gene: Study

It is estimated that more than 7,000 people are diagnosed with head and neck cancer each year in the UK and approximately 3,500 cases result in death. These cancers include tumours of the mouth, lips, throat and voice-box, and some have been linked to the sexually transmitted infection, HPV-16. Scientists at Liverpool analysed the DNA of more than 90 cancerous tissue samples to look for genes that indicated infection.

6 Oct 2009

Scientists identify new interference method to target cancer cells

Professor Jo Milner and Dr Shafiq Ahmed, from the YCR P53 Research Unit in the Department of Biology, used a process called RNA interference to target the JNK2 gene in both cancer and healthy cells. The cancer cells died but the healthy cells were unaffected.

6 Oct 2009

FDA's Oncologic Drugs Advisory Committee recommends approval of GlaxoSmithKline's VOTRIENT

GlaxoSmithKline today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in support of the approval of VOTRIENT(TM) (pazopanib). Specifically, the panel voted that the benefit-to-risk profile is acceptable for patients with advanced renal cell carcinoma (RCC). Pazopanib is an investigational, oral treatment for patients with advanced RCC.

6 Oct 2009

Positive results from Peregrine's Phase II bavituximab trial for non-small cell lung cancer

Peregrine Pharmaceuticals, Inc. today reported additional positive results in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC). Data previously reported from the initial cohort of 21 patients in the study had indicated that 11 of 17 evaluable patients with locally advanced or metastatic NSCLC achieved an objective tumor response according to RECIST criteria.

5 Oct 2009

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

Seattle Genetics, Inc. announced today that it has discontinued the SeaGen MARINER clinical trial based on a determination that the trial would be unlikely to meet its primary endpoint of superior complete response rate in the dacetuzumab combination arm as compared to the placebo combination arm.

5 Oct 2009

Willow Breast Cancer Support Canada calls for national Metastatic Breast Cancer Awareness Day

Thousands of Canadian women with metastatic breast cancer and their loved ones are marking the first Canadian Metastatic Breast Cancer Awareness Day on October 13, urging Canadians to acknowledge them and delivering the message that "hope changes."

5 Oct 2009

Scientists uncover the role of first-responder molecule involved in repairing DNA strand breaks

Scientists from the U.S. Department of Energy's Lawrence Berkeley National Laboratory and the Scripps Research Institute have uncovered the role played by the least-understood part of a first-responder molecule that rushes in to bind and repair breaks in DNA strands, a process that helps people avoid cancer.

5 Oct 2009

Chemotherapy News and Research

Latest Chemotherapy News and Research

Study: Patients experience sleep apnea after opharyngeal cancer treatment

Combination of leukemia and breast cancer drugs inhibits cancer progression

Stereotactic Radiosurgery for metastatic brain tumors reduces risks of learning and memory problems

Scientists create new technology to improve detection of leukemia cells in bone marrow

Scrapbooking Marathon to raise funds for breast cancer awareness and research

Pro-Pharmaceuticals closes $325,000 tranche of private placement; total raised to $3.8 million

iMedicor to market Access Pharmaceuticals' MuGard in North America

OncoGenex' OGX-011 receives additional FDA Fast Track Designation for treating metastatic prostate cancer

New embolization technique offers better clinical outcomes in the treatment of liver cancer

NYBC encourages people to organize community blood drives

New fruit-flavored protein drinks for nutritionally challenged

Elekta Impac Software to demonstrate its integrated oncology EHR, MOSAIQ at EHR Symposium

EP-100 membrane-disrupting peptide drug for cancer being tested at TCRS

Two-thirds of tonsil tumour samples show evidence of HPV-16 gene: Study

Scientists identify new interference method to target cancer cells

FDA's Oncologic Drugs Advisory Committee recommends approval of GlaxoSmithKline's VOTRIENT

Positive results from Peregrine's Phase II bavituximab trial for non-small cell lung cancer

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

Willow Breast Cancer Support Canada calls for national Metastatic Breast Cancer Awareness Day

Scientists uncover the role of first-responder molecule involved in repairing DNA strand breaks

Cancer Research eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Newsletters you may be interested in